All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, May 27, 2023
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Analysts: Interest In Antisense Waning, But Science Not Dead

Sep. 16, 2005
By Karen Carey
No Comments

Other News To Note

Sep. 13, 2005
No Comments

Other News To Note

July 20, 2005
No Comments

ACE2 Receptor Is New Drug Target In SARS Lung Failure

July 13, 2005
By Sharon Kingman
No Comments

Found Coronavirus Might Have Ties To Pediatric Heart Disease

Feb. 11, 2005
By Anette Breindl
No Comments

Driving A Spike Through Heart Of SARS Proving Challenging

Jan. 18, 2005
By Anette Breindl
No Comments

Other News To Note

Dec. 7, 2004
No Comments

Other News To Note

Oct. 13, 2004
No Comments

Other News To Note

Oct. 12, 2004
No Comments

From Cellular Trash To Receptor Families, Awards Season Arrives

Oct. 7, 2004
By Anette Breindl
No Comments
Previous 1 2 … 500 501 502 503 504 505 506 507 508 509 510 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 26, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 26, 2023.
  • FDA approved icons and medical professional

    Genmab, Abbvie to join Roche with FDA nod for CD20 bispecific in lymphoma

    BioWorld
    Five months after the first anti-CD20xCD3 T-cell engaging bispecific antibody, Roche Holding AG’s Lunsumio (mosunetuzumab), cleared U.S. FDA approval for...
  • Illustration of pancreas

    Gene therapy to reverse T2D shows proof of concept at ASGCT

    BioWorld
    The most ambitious objective of any treatment is to eradicate the disease, acting on its origin to cure it instead of treating its symptoms. This is the purpose...
  • PET imaging of RELN-COLBOS (H3447R) carrier brain showing limited aggregation of tau

    Reelin’ in druggable protective pathways with second Alzheimer’s ‘escapee’

    BioWorld
    Investigators have identified a second individual who remained cognitively normal into his late 60s despite having the PSEN1 E280A mutation, which causes a...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing